BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1600
+0.0900 (+8.41%)
At close: 3:59PM EDT

1.1500 -0.01 (-0.86%)
After hours: 4:10PM EDT

Stock chart is not supported by your current browser
Previous Close1.0700
Open1.0800
Bid1.1500 x 4000
Ask1.1700 x 1100
Day's Range1.0700 - 1.1700
52 Week Range0.6600 - 12.1500
Volume1,219,015
Avg. Volume4,404,522
Market Cap21.886M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-5.2150
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.42
Trade prices are not sourced from all markets
  • Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
    PR Newswire6 days ago

    Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel

    Biocept continues to expand its commercial offering for breast cancer and remains the only liquid biopsy provider to offer single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis ...

  • Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4
    PR Newswire21 days ago

    Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4

    SAN DIEGO , June 3, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • PR Newswire27 days ago

    Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally

    The patent encompasses the use of any biological sample type of interest and is the 33rd patent issued to Biocept that is core to its liquid biopsy technology and commercial testing platforms. "The granting of this patent further expands Biocept's international footprint for capturing and analyzing rare cells from biological fluids, such as blood, bone marrow, cerebral spinal fluid (CSF), and tissue, to assess the status of patients with cancer," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept.

  • MarketWatchlast month

    Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer

    Shares of Biocept Inc. soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. Trading volume spiked to 60.9 million shares, compared with the full-day average of about 733,000 shares. "The Target Selector™ NGS Lung Panel will be marketed to physicians and researchers, and can be used to detect and monitor actionable biomarkers associated with lung cancer," the company said in a statement. The stock was still down 73% over the past 12 months, while the S&P 500 has gained 4.5%.

  • Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
    PR Newswirelast month

    Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer

    Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , May 20, 2019 /PRNewswire/ ...

  • Biocept Reports First Quarter 2019 Financial Results
    PR Newswire2 months ago

    Biocept Reports First Quarter 2019 Financial Results

    - Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened ...

  • Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
    PR Newswire2 months ago

    Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019

    SAN DIEGO , May 1, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information ...

  • Biocept Reports 2018 Fourth Quarter and Full Year Financial Results
    PR Newswire3 months ago

    Biocept Reports 2018 Fourth Quarter and Full Year Financial Results

    Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized ...

  • Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment
    PR Newswire3 months ago

    Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment

    Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO ...

  • Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019
    PR Newswire3 months ago

    Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019

    SAN DIEGO , March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...

  • Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device
    PR Newswire3 months ago

    Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device

    Biocept believes the newly granted patent has claims that encompass any biological sample type of interest, and is the 32nd patent issued to Biocept that is core to its liquid biopsy technology platforms. The technology covered by this issued patent combines Biocept's patented microchannel platform together with antibodies to enable the capture of rare cells of interest.

  • ACCESSWIRE3 months ago

    Biocept, Potential Near-Term Catalysts for Biocept

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Biocept Announces Pricing of $8.2 Million Registered Direct Offering
    PR Newswire3 months ago

    Biocept Announces Pricing of $8.2 Million Registered Direct Offering

    SAN DIEGO, March 15, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $8.2 million of its common stock in a registered direct offering and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $1.37. Under the terms of the purchase agreement, Biocept has agreed to sell approximately 5,950,000 shares of its common stock.

  • Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services
    PR Newswire3 months ago

    Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services

    SAN DIEGO, March 13, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has expanded its pathology partnership platform, EmpowerTCTM, to now offer local pathologists the ability to analyze prognostic and predictive markers on CTCs from a liquid biopsy using immunocytochemistry (ICC) methods. This new offering, in addition to an expanded biomarker menu, supplements the previous capabilities of Biocept's proprietary pathology partnership platform to analyze liquid biopsy biomarkers using fluorescence in situ hybridization (FISH) methods.

  • Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting
    PR Newswire4 months ago

    Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting

    SAN DIEGO, March 4, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that its abstract demonstrating the ability of the Company's Target Selector™ liquid biopsy test to detect ESR1 mutations with high sensitivity has been accepted for a poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 at the Georgia World Congress Center in Atlanta.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Getting A Boost On Wednesday

    While industries like tech and auto develop innovative technologies for consumers, by and large, people can survive without their devices and their cars, but our health supersedes all else. The unrivaled importance of the healthcare sector comes with the expectation that companies working in the space are prepared to meet the growing demands of patients suffering from a multitude of diseases. If healthcare companies continue to provide the best quality care for their patients, this may, in turn, spark investor excitement.

  • Biocept and Providence Saint John's Health Center Collaborate to Evaluate Cerebrospinal Fluid for Use with Liquid Biopsy Testing in Metastatic Cancer
    PR Newswire4 months ago

    Biocept and Providence Saint John's Health Center Collaborate to Evaluate Cerebrospinal Fluid for Use with Liquid Biopsy Testing in Metastatic Cancer

    Saint John's and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company's Target Selector™ assay platform in patients with known or suspected brain metastases SAN DIEGO , Feb. ...

  • Biocept Issues Letter to Stockholders
    PR Newswire4 months ago

    Biocept Issues Letter to Stockholders

    Focus on new market segments and strategies to drive growth SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Biocept, Inc.  (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide ...

  • What Makes Biocept (BIOC) a New Buy Stock
    Zacks4 months ago

    What Makes Biocept (BIOC) a New Buy Stock

    Biocept (BIOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Biocept Announces Pricing of $7.5 Million Underwritten Public Offering
    PR Newswire4 months ago

    Biocept Announces Pricing of $7.5 Million Underwritten Public Offering

    SAN DIEGO, Feb. 8, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock and warrants to purchase up to 6,250,000 shares of the Company's common stock.  Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $1.20 per share and warrant.  Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $7.5 million.

  • Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits
    PR Newswire5 months ago

    Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits

    SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the world for both research and clinical applications. Under the agreement, Agiomix plans to validate Biocept's patented and proprietary liquid biopsy technology in order to perform testing for the detection of tumor biomarkers.

  • Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful
    PR Newswire5 months ago

    Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful

    SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed article featuring a case series of three patients indicating the clinical utility of Biocept's Target Selector™ circulating tumor DNA (ctDNA) testing in the management of patients with advanced non-small cell lung cancer (NSCLC). In each of the three patient cases, Biocept's liquid biopsy testing detected activating EGFR mutations where tissue biopsy was inadequate, and targeted EGFR-directed therapy was subsequently administered.

  • ACCESSWIRE5 months ago

    Biocept, Inc., Pipeline Review, Upcoming Catalysts and Milestones

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Biocept, Inc. (BIOC), a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept is an emerging player in the liquid biopsy space and the key for Biocept is to continue to raise awareness about its technology platform.

  • Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA
    PR Newswire5 months ago

    Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA

    SAN DIEGO, Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits, which are intended to enable molecular laboratories around the world to utilize Biocept's Target Selector™ circulating tumor DNA (ctDNA) assays to perform liquid biopsy testing.  Biocept's Target Selector™ platform is patent protected in the United States and in 10 major international territories. The first available kit is for the high-sensitivity detection of EGFR oncogene mutations, which are among the most frequently evaluated biomarkers for lung cancer.

  • Should You Worry About Biocept, Inc.’s (NASDAQ:BIOC) CEO Salary Level?
    Simply Wall St.5 months ago

    Should You Worry About Biocept, Inc.’s (NASDAQ:BIOC) CEO Salary Level?

    Mike Nall has been the CEO of Biocept, Inc. (NASDAQ:BIOC) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...